Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EPS (Basic): 2011-2025

Historic EPS (Basic) for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to -$3.84.

  • Enanta Pharmaceuticals' EPS (Basic) rose 35.29% to -$0.88 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.84, marking a year-over-year increase of 29.93%. This contributed to the annual value of -$3.84 for FY2025, which is 29.93% up from last year.
  • Enanta Pharmaceuticals' EPS (Basic) amounted to -$3.84 in FY2025, which was up 29.93% from -$5.48 recorded in FY2024.
  • In the past 5 years, Enanta Pharmaceuticals' EPS (Basic) ranged from a high of -$3.84 in FY2025 and a low of -$6.38 during FY2023.
  • For the 3-year period, Enanta Pharmaceuticals' EPS (Basic) averaged around -$5.23, with its median value being -$5.48 (2024).
  • As far as peak fluctuations go, Enanta Pharmaceuticals' EPS (Basic) slumped by 116.57% in 2021, and later rose by 29.93% in 2025.
  • Yearly analysis of 5 years shows Enanta Pharmaceuticals' EPS (Basic) stood at -$3.92 in 2021, then plummeted by 50.77% to -$5.91 in 2022, then decreased by 7.95% to -$6.38 in 2023, then rose by 14.11% to -$5.48 in 2024, then increased by 29.93% to -$3.84 in 2025.